NCT05332834View on ClinicalTrials.gov

A Phase 1 Study of Single and Multiple Intravenous Doses of SM17 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

77

Participants

Timeline

Start Date

June 14, 2022

Primary Completion Date

September 26, 2023

Study Completion Date

September 26, 2023

Conditions

Asthma

Interventions

BIOLOGICAL

SM17

Peripheral intravenous injection

OTHER

Placebo

Peripheral intravenous injection

Trial Locations (1)

68502

Celerion Lincoln, Lincoln

All Listed Sponsors

lead

SinoMab BioScience Ltd

INDUSTRY